| 9:00 9:15 | Welcome |
| | Opening Remarks, Hans Scheurer, MPE President, and Ananda Plate, MPE CEO |
| 9.15 10.45 | AL Amyloidosis & other MM related diseases |
| | Developments in AL amyloidosis: diagnostic centres of expertise, treatment pathway, and stages of the disease, Monique Minnema, MD, PhD University Medical Center Utrecht, the Netherlands |
| | Myeloma related diseases, their presentation and effects on symptoms and quality of life, Paolo Milani, MD, PhD, University of Pavia, Pavia, Italy |
| | Moderated Q&A |
| 10.45 11.00 | Coffee break |
| 11.00 12.30 | Access to new treatments |
| | Immunotherapy in the treatment of myeloma and AL amyloidosis, Marivi Mateos |
| | A clinical perspective on access in central and eastern European and Balkan countries, Roman Hájek, M.D., Ph.D., University Hospital Ostrava, Czech Republic |
| | Moderated Q&A |
| 12.30 13.30 | Lunch break |
| 13.30 15.00 | Empowering Patient Organisations |
| | Palliative Care and quality of life, Christina Gerlach, M.D. |
| | Fundraising for patient groups and collaboration with industry, Jan Geissler, Chair, Workgroup of European Cancer Patient Advocacy Networks (WECAN) |
| 15:00 15:15 | Coffee Break |
| 15.15 16.45 | Panel discussion on Minimal Residual Disease (MRD) |
| | Hans Jacobs, M.D., Ph.D., Medical Immunologist, Radboud University Medical Center, NL |
| | Paula van Hennik, Committee for Medicinal Products for Human Use (CHMP) and member at the European Medicine Agency (EMA) |
| | Hans Scheurer, MPE President |
| 16.45 17.00 | Wrap up and close, Hans Scheurer, MPE President, and Ananda Plate, MPE CEO |
